Abstract:

ABSTRACT: Focal segmental glomerulosclerosis (FSGS) is a common primary glomerular disorder. The prognosis of FSGS is closely related to the reponse of treatment. Glucocoticosteroid and calcineurin inhibitors are the first-line drugs in the treatment of FSGS patients with nephrotic syndrome. Most patients can attain remission of proteinuria and have a good prognosis. However, some of the patients have sustained massive proteinuria, despite treated by a variety of drugs, and evolve to ESRD rapidly. For these refractory patients, new drugs may bring the hope of mend. In pace with understanding of the pathogenesis of FSGS, more therapeutic targets and drugs have developed, but the curative effect should be further tested and verified.

Key words: Focal segmental glomerulosclerosis, treatment, Glucocorticosteroid, Calcineurin inhibitor